MX390385B - Anticuerpos anti-pd-l1. - Google Patents
Anticuerpos anti-pd-l1.Info
- Publication number
- MX390385B MX390385B MX2017001597A MX2017001597A MX390385B MX 390385 B MX390385 B MX 390385B MX 2017001597 A MX2017001597 A MX 2017001597A MX 2017001597 A MX2017001597 A MX 2017001597A MX 390385 B MX390385 B MX 390385B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- methods
- present
- binding fragments
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014083715 | 2014-08-05 | ||
| PCT/US2015/043723 WO2016022630A1 (en) | 2014-08-05 | 2015-08-05 | Anti-pd-l1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017001597A MX2017001597A (es) | 2017-11-17 |
| MX390385B true MX390385B (es) | 2025-03-20 |
Family
ID=55264464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001597A MX390385B (es) | 2014-08-05 | 2015-08-05 | Anticuerpos anti-pd-l1. |
| MX2022002364A MX2022002364A (es) | 2014-08-05 | 2017-02-03 | Anticuerpos anti-pd-l1. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002364A MX2022002364A (es) | 2014-08-05 | 2017-02-03 | Anticuerpos anti-pd-l1. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10435470B2 (enExample) |
| EP (1) | EP3177649B1 (enExample) |
| JP (2) | JP6909153B2 (enExample) |
| KR (1) | KR102476226B1 (enExample) |
| CN (4) | CN107001463B (enExample) |
| AU (2) | AU2015301126B2 (enExample) |
| CA (1) | CA2956399A1 (enExample) |
| ES (1) | ES2987034T3 (enExample) |
| IL (1) | IL250415B (enExample) |
| MX (2) | MX390385B (enExample) |
| NZ (1) | NZ728749A (enExample) |
| RU (1) | RU2722212C9 (enExample) |
| SG (2) | SG10201901057UA (enExample) |
| WO (1) | WO2016022630A1 (enExample) |
| ZA (1) | ZA201700785B (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| KR102761886B1 (ko) | 2015-07-30 | 2025-02-06 | 마크로제닉스, 인크. | Pd-1-결합 분자 및 그것의 사용 방법 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| CA3013558C (en) | 2016-02-05 | 2024-11-12 | Universiteit Gent | CD8 LIAISON OFFICERS |
| DK3455257T3 (da) * | 2016-05-09 | 2021-11-01 | Igm Biosciences Inc | Anti-pd-l1-antistoffer |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN105968200B (zh) * | 2016-05-20 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-l1人源化单克隆抗体及其应用 |
| CN106008714B (zh) | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| CN107460221B (zh) * | 2016-06-02 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 |
| WO2017218435A1 (en) * | 2016-06-13 | 2017-12-21 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| TW201803905A (zh) * | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3497129A1 (en) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| KR102604433B1 (ko) | 2016-08-09 | 2023-11-24 | 키맵 리미티드 | 항-icos 항체 |
| US11317611B2 (en) | 2016-08-31 | 2022-05-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric PD-L1 |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018077893A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN108203720A (zh) * | 2016-12-20 | 2018-06-26 | 上海生博生物医药科技有限公司 | 能靶向Her2并封闭PD-L1降低肿瘤免疫逃逸的CAR-T载体及其构建方法和应用 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| CN108456251A (zh) * | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
| RU2665790C1 (ru) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| CN107267555B (zh) | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| CN107299110B (zh) * | 2017-05-27 | 2019-11-22 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用 |
| CN107164410B (zh) * | 2017-05-27 | 2019-09-03 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN111246886B (zh) * | 2017-11-02 | 2022-03-15 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| CN115925943A (zh) * | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| KR102311838B1 (ko) * | 2017-12-27 | 2021-10-14 | 주식회사 파멥신 | 항-pd-l1 항체 및 이의 용도 |
| KR102845020B1 (ko) * | 2017-12-28 | 2025-08-12 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-l1에 대한 항체 및 변이체 |
| MX2020007406A (es) * | 2018-01-10 | 2020-09-14 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| CN112424222A (zh) * | 2018-02-17 | 2021-02-26 | 冠科美博有限公司 | 使用中性粒细胞调节剂与免疫检查点调节剂的组合的癌症治疗 |
| JP2021518380A (ja) * | 2018-03-19 | 2021-08-02 | アベオメ コーポレーション | プログラム細胞死リガンド１（ｐｄ−ｌ１）に対する高親和性中和モノクローナル抗体、及びその使用 |
| IL297847B2 (en) * | 2018-04-09 | 2024-02-01 | Origincell Therapeutics Co Ltd | Anti-PD-L1 antibody and its use |
| TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類ｐｄ-ｌ１之抗體及其用途 |
| WO2020041404A1 (en) * | 2018-08-23 | 2020-02-27 | Macrogenics, Inc. | Pd-l1-binding molecules and use of the same for the treatment of disease |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| TWI840442B (zh) | 2018-11-13 | 2024-05-01 | 美商坎伯斯治療有限責任公司 | 對抗檢查點分子之多特異性結合構築體及其用途 |
| HUE067601T2 (hu) | 2018-11-14 | 2024-10-28 | Regeneron Pharma | PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére |
| WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| BR112021012688A2 (pt) * | 2018-12-27 | 2021-09-08 | Gigagen, Inc. | Proteínas de ligação anti-pd-l1 e métodos de uso das mesmas |
| CN113347996B (zh) * | 2019-01-25 | 2024-04-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| JP2022521800A (ja) | 2019-02-28 | 2022-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
| US12187792B2 (en) | 2019-03-06 | 2025-01-07 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN119770644A (zh) * | 2019-03-15 | 2025-04-08 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的联用药物组合物 |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| CN113939315B (zh) * | 2019-05-30 | 2024-04-02 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗黑色素瘤的联用药物组合物 |
| WO2020249018A1 (zh) * | 2019-06-10 | 2020-12-17 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗驱动基因阳性肺癌的联用药物组合物 |
| US20220306713A1 (en) * | 2019-06-10 | 2022-09-29 | Apollomics Inc. (Hangzhou) | Antibody-interleukin fusion protein and methods of use |
| CN112168961A (zh) * | 2019-07-03 | 2021-01-05 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4023679A4 (en) * | 2019-08-30 | 2023-10-04 | Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group | FUSION PROTEIN TARGETING PD-L1 AND TGF-BETA AND USE THEREOF |
| TWI832013B (zh) * | 2019-09-30 | 2024-02-11 | 大陸商諾納生物（蘇州）有限公司 | 一種抗pd-l1抗原結合蛋白及其應用 |
| JP2023500156A (ja) * | 2019-11-08 | 2023-01-04 | チャンスー シムサー ファーマシューティカル カンパニー リミテッド | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| IL272389A (en) * | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
| CA3170330A1 (en) * | 2020-02-21 | 2021-08-26 | Macrogenics, Inc. | Cd137 binding molecules and uses thereof |
| CN113318226A (zh) * | 2020-02-28 | 2021-08-31 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 |
| CN120463810A (zh) | 2020-04-02 | 2025-08-12 | 正大天晴药业集团股份有限公司 | 结合cd47的抗原结合多肽及用途 |
| CA3181598A1 (en) * | 2020-04-30 | 2021-11-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination drug for treating kidney cancer |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| AU2021280245A1 (en) | 2020-05-26 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering a PD-1 inhibitor |
| CN115697407A (zh) | 2020-06-02 | 2023-02-03 | 正大天晴药业集团股份有限公司 | c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物 |
| EP4174087A4 (en) | 2020-06-30 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MEDICATION FOR TUMOR TREATMENT |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| CN116113411A (zh) * | 2020-08-13 | 2023-05-12 | 正大天晴药业集团股份有限公司 | 用于治疗软组织肉瘤的联用药物 |
| MX2023002123A (es) | 2020-08-26 | 2023-03-15 | Regeneron Pharma | Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1. |
| EP4208258A1 (en) | 2020-09-03 | 2023-07-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer pain by administering a pd-1 inhibitor |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| EP4303231A4 (en) | 2021-02-07 | 2025-02-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BISPECIFIC ANTIBODY |
| MX2023011007A (es) | 2021-03-23 | 2023-12-07 | Regeneron Pharma | Metodos para tratar el cancer en pacientes inmunosuprimidos o inmunocomprometidos mediante la administracion de un inhibidor de pd-1. |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| WO2022206752A1 (zh) | 2021-03-29 | 2022-10-06 | 正大天晴药业集团股份有限公司 | Toll样受体7激动剂和抗PD-L1抗体的药物联合 |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| IL309831A (en) | 2021-07-13 | 2024-02-01 | BioNTech SE | Multispecific binding agents against CD40 and CD137 in combined cancer therapy |
| US20230139492A1 (en) | 2021-07-19 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
| US20240316031A1 (en) | 2021-07-22 | 2024-09-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| AU2022321783A1 (en) | 2021-08-05 | 2024-03-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition for treating small cell lung cancer |
| CN117642181A (zh) * | 2021-09-06 | 2024-03-01 | 正大天晴药业集团股份有限公司 | 用于治疗食管癌的药物组合 |
| KR20240056587A (ko) | 2021-09-16 | 2024-04-30 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항-her3 항체 약물 접합체, 이의 조성물, 및 이의 용도 |
| EP4410836A1 (en) | 2021-09-30 | 2024-08-07 | Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group | Anti-cd47 antibody for combined treatment of blood tumor |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN118201963A (zh) | 2021-12-01 | 2024-06-14 | 正大天晴药业集团股份有限公司 | 用于治疗非小细胞肺癌的药物组合 |
| WO2023159102A1 (en) | 2022-02-17 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Combinations of checkpoint inhibitors and oncolytic virus for treating cancer |
| CN118871128A (zh) * | 2022-03-18 | 2024-10-29 | 正大天晴药业集团南京顺欣制药有限公司 | 抗tim-3抗体与抗pd-l1抗体的药物组合 |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| CN119278053A (zh) * | 2022-06-02 | 2025-01-07 | 正大天晴药业集团股份有限公司 | 用于治疗子宫恶性肿瘤的药物组合 |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| WO2024228167A1 (en) | 2023-05-03 | 2024-11-07 | Iox Therapeutics Inc. | Inkt cell modulator liposomal compositions and methods of use |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025080538A1 (en) | 2023-10-09 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
| CN117783521B (zh) * | 2023-11-23 | 2025-03-04 | 中国农业科学院兰州兽医研究所 | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| CN120865416B (zh) * | 2025-09-28 | 2025-12-30 | 成都微芯新域生物技术有限公司 | 抗mica/b抗体及其应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5994514A (en) | 1991-08-14 | 1999-11-30 | Genentech, Inc. | Immunoglobulin variants |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JPH07291996A (ja) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| HUP0202882A2 (en) | 1999-08-23 | 2002-12-28 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| AU6015301A (en) | 2000-03-24 | 2001-10-03 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| AU2002224037A1 (en) | 2000-11-15 | 2002-05-27 | Tasuku Honjo | Pd-1-lacking mouse and use thereof |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| US7608429B2 (en) | 2002-10-31 | 2009-10-27 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ４抗体 |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| CN1296385C (zh) | 2005-03-30 | 2007-01-24 | 王哲 | 抗猪生长激素单克隆抗体及制备方法及应用 |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| HRP20080053A2 (hr) * | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| WO2007064972A2 (en) * | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
| CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
| CN101421303B (zh) | 2006-03-23 | 2013-06-12 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| ATE552245T1 (de) | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| US7927590B2 (en) | 2006-07-10 | 2011-04-19 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
| CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| WO2008083174A2 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| US7615883B2 (en) | 2007-06-06 | 2009-11-10 | Meheen H Joe | Wind driven venturi turbine |
| AU2014201367B2 (en) | 2007-06-18 | 2016-01-28 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| US9243052B2 (en) | 2007-08-17 | 2016-01-26 | Daniel Olive | Method for treating and diagnosing hematologic malignancies |
| ES2636460T3 (es) * | 2007-10-08 | 2017-10-05 | Intrexon Corporation | Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer |
| CA2702939A1 (en) | 2007-10-16 | 2009-04-23 | Sbi Biotech Co., Ltd. | Anti-bst2 antibody |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| US9181342B2 (en) | 2008-09-12 | 2015-11-10 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2013204861B2 (en) * | 2008-09-26 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| CA3120172A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| US8741295B2 (en) * | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| DK2406284T5 (en) * | 2009-03-10 | 2017-06-12 | Biogen Ma Inc | ANTI-BCMA ANTIBODIES |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP5774595B2 (ja) | 2009-10-28 | 2015-09-09 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｇｌｐ−１ｒ抗体及びそれらの使用 |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| KR101926663B1 (ko) | 2010-02-19 | 2018-12-07 | 젠코어 인코포레이티드 | 신규의 ＣＴＬＡ４-Ｉｇ 이뮤노어드헤신 |
| US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
| WO2011120134A1 (en) | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| HRP20181690T4 (hr) | 2011-03-29 | 2025-01-03 | Roche Glycart Ag | Varijante protutijela fc |
| EP2691112B1 (en) | 2011-03-31 | 2018-05-23 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| KR20140081757A (ko) | 2011-05-02 | 2014-07-01 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 다발성골수종 치료방법 |
| RU2616881C2 (ru) | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| CN102836441B (zh) * | 2011-06-24 | 2019-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP2844289B1 (en) | 2012-04-30 | 2019-07-17 | MedImmune, LLC | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| WO2014007982A2 (en) | 2012-07-03 | 2014-01-09 | Janssen Alzheimer Immunotherapy | C-terminal and central epitope a-beta antibodies |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| US10034939B2 (en) | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| US20140377269A1 (en) | 2012-12-19 | 2014-12-25 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN105734081A (zh) | 2013-02-20 | 2016-07-06 | 瑞泽恩制药公司 | 具有修饰的免疫球蛋白重链序列的非人类动物 |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
-
2015
- 2015-08-05 SG SG10201901057UA patent/SG10201901057UA/en unknown
- 2015-08-05 NZ NZ728749A patent/NZ728749A/en unknown
- 2015-08-05 ES ES15829791T patent/ES2987034T3/es active Active
- 2015-08-05 CN CN201580042278.8A patent/CN107001463B/zh active Active
- 2015-08-05 CA CA2956399A patent/CA2956399A1/en active Pending
- 2015-08-05 CN CN202310833274.8A patent/CN118388646A/zh active Pending
- 2015-08-05 WO PCT/US2015/043723 patent/WO2016022630A1/en not_active Ceased
- 2015-08-05 KR KR1020177005642A patent/KR102476226B1/ko active Active
- 2015-08-05 CN CN201911310366.8A patent/CN110964109B/zh active Active
- 2015-08-05 US US15/328,232 patent/US10435470B2/en active Active
- 2015-08-05 EP EP15829791.1A patent/EP3177649B1/en active Active
- 2015-08-05 JP JP2017506285A patent/JP6909153B2/ja active Active
- 2015-08-05 RU RU2017106804A patent/RU2722212C9/ru active
- 2015-08-05 CN CN201911310359.8A patent/CN110964108B/zh active Active
- 2015-08-05 MX MX2017001597A patent/MX390385B/es unknown
- 2015-08-05 AU AU2015301126A patent/AU2015301126B2/en active Active
- 2015-08-05 SG SG11201700687TA patent/SG11201700687TA/en unknown
-
2017
- 2017-02-01 ZA ZA2017/00785A patent/ZA201700785B/en unknown
- 2017-02-02 IL IL250415A patent/IL250415B/en active IP Right Grant
- 2017-02-03 MX MX2022002364A patent/MX2022002364A/es unknown
-
2019
- 2019-08-12 US US16/538,440 patent/US11111300B2/en active Active
-
2020
- 2020-03-31 JP JP2020063112A patent/JP7144477B2/ja active Active
-
2021
- 2021-06-02 AU AU2021203593A patent/AU2021203593B2/en active Active
- 2021-08-11 US US17/399,891 patent/US11827707B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390385B (es) | Anticuerpos anti-pd-l1. | |
| MX2017000985A (es) | Anticuerpos anti-pd-1. | |
| IL269002A (en) | Antibodies against pd-l1 | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| CL2018000595A1 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| CO2018005614A2 (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos | |
| GEAP202114453A (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
| CL2016002460A1 (es) | Anticuerpos biespecíficos que se unen a cd38 y cd3 | |
| DK3441086T3 (da) | Monoklonalt anti-PD-1-antistof | |
| DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
| DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
| EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
| CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
| CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
| EP3433277A4 (en) | NEW ANTI-PD-L1 ANTIBODIES | |
| CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| BR112016022658A2 (pt) | anticorpos anti-ox40 e métodos de uso | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
| EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
| IL248402B (en) | Humanized antibodies against ceacam1 |